OBM Geriatrics is an Open Access journal published quarterly online by LIDSEN Publishing Inc. The journal takes the premise that innovative approaches – including gene therapy, cell therapy, and epigenetic modulation – will result in clinical interventions that alter the fundamental pathology and the clinical course of age-related human diseases. We will give strong preference to papers that emphasize an alteration (or a potential alteration) in the fundamental disease course of Alzheimer’s disease, vascular aging diseases, osteoarthritis, osteoporosis, skin aging, immune senescence, and other age-related diseases.
Geriatric medicine is now entering a unique point in history, where the focus will no longer be on palliative, ameliorative, or social aspects of care for age-related disease, but will be capable of stopping, preventing, and reversing major disease constellations that have heretofore been entirely resistant to interventions based on “small molecular” pharmacological approaches. With the changing emphasis from genetic to epigenetic understandings of pathology (including telomere biology), with the use of gene delivery systems (including viral delivery systems), and with the use of cell-based therapies (including stem cell therapies), a fatalistic view of age-related disease is no longer a reasonable clinical default nor an appropriate clinical research paradigm.
Precedence will be given to papers describing fundamental interventions, including interventions that affect cell senescence, patterns of gene expression, telomere biology, stem cell biology, and other innovative, 21st century interventions, especially if the focus is on clinical applications, ongoing clinical trials, or animal trials preparatory to phase 1 human clinical trials.
Papers must be clear and concise, but detailed data is strongly encouraged. The journal publishes research articles, reviews, communications and technical notes. There is no restriction on the length of the papers and we encourage scientists to publish their results in as much detail as possible.
Archiving: full-text archived in CLOCKSS.
Publication Speed (median values for papers published in 2022): Submission to First Decision: 5 weeks; Submission to Acceptance: 14 weeks; Acceptance to Publication: 11 days (1-2 days of FREE language polishing included)
Oxidative Stress and Alzheimer’s Disease
Submission Deadline: August 30, 2019 (Open) Submit Now
Luigi Iuliano, MD
Professor, Department of Medical Sciences and Biotechnology, Sapienza University of Rome, Italy
Research Interests: oxidative stress related disorders; atherosclerosis and neurodegenerative diseases; clinical and epidemiological studies; oxidative stress; oxidative stress biomarkers
About This Topic
Alzheimer’s disease (AD) is the most frequent form of neurodegenerative disorder associated with dementia in the elderly. The expansion in the prevalence of this disease due to the increase in life expectancy is a worldwide socioeconomic challenge. As for other forms of dementia, there is no cure for AD and intense research is ongoing to determine pathophysiological mechanisms and to find targeted therapies. AD is influenced by both genetic and epigenetic risk factors. The strongest genetic risk factor is the presence of the epsilon4 allele of the apolipoprotein E gene, which encodes a protein that has a crucial role in cholesterol metabolism. However, the role of genetic factors is more confined to the early onset of disease, which constitutes a fraction of the AD burden observed in the elderly. Among epigenetic factors, oxidative stress, which results from high free radical flux unbalanced by the antioxidant system and leads to damage of biomolecules resulting in cellular insult, is a well-known pathophysiological player in neurodegenerative disorders. The link between oxidative stress and AD is solidly supported by basic and translational research and new aspects continues to emerge in the literature. As Guest Editor for this Special Issue of the journal OBM Geriatrics, it is my pleasure to invite you to submit a feature article, which may be either a review or a research paper, on the topic of Oxidative Stress and Alzheimer’s Disease.
Received: 05 May 2019; Published: 17 July 2019; doi: 10.21926/obm.geriatr.1903064
The yeast, Saccharomyces cerevisiae, the model eukaryote, has provided many insights into molecular and cellular biology, as well as insights into many human diseases. In this paper we present some insights on how yeast studies are contributing to knowledge about the role of oxidative damage to cell health, and how one of the key players [...]
To prevent robots and page crawlers from submitting fraudulent forms, complete verification to prove that you are a human.